99TH GENERAL ASSEMBLY
State of Illinois
2015 and 2016
HB2790
 
Introduced , by Rep. Laura Fine
 
SYNOPSIS AS INTRODUCED:



410 ILCS 240/3.4 new

 Amends the Newborn Metabolic Screening Act. Requires the Department of Public Health to provide all newborns with screening tests for the presence of adrenoleukodystrophy (ALD). Provides that testing shall begin within 12 months following the occurrence of various events, including: (1) the development and validation of a reliable methodology; (2) the availability of any necessary reagents; (3) the establishment and verification of relevant and appropriate performance specifications; (4) the availability of quality assurance testing; (5) the acquisition and installment of necessary equipment; (6) the establishment of precise threshold values ensuring defined disorder identification for ALD; (7) the authentication of pilot testing; and (8) the authentication of achieving the potential of high throughput standards. Allows the Department to implement an additional fee for the screening prior to beginning the testing in order to accumulate the resources for start-up and other costs associated with implementation of the screening and thereafter to support the costs associated with screening and follow-up programs for adrenoleukodystrophy.



LRB099 03689 JLK 23700 b


 
 
A BILL FOR
 


HB2790LRB099 03689 JLK 23700 b



1 AN ACT concerning health.


2 Be it enacted by the People of the State of Illinois,

3represented in the General Assembly:



4 Section 5. The Newborn Metabolic Screening Act is amended 
5by adding Section 3.4 as follows:

6 (410 ILCS 240/3.4 new)
7 Sec. 3.4. Adrenoleukodystrophy. In accordance with the 
8timetable specified in this Section, the Department shall 
9provide all newborns with screening tests for the presence of 
10adrenoleukodystrophy (ALD). The testing shall begin within 12 
11months following the occurrence of all of the following:
12  (1) the development and validation of a reliable 
13 methodology for screening newborns for ALD using dried 
14 blood spots and quality assurance testing methodology for 
15 such test or the approval of a test for ALD using dried 
16 blood spots by the federal Food and Drug Administration;
17  (2) the availability of any necessary reagents for such 
18 test;
19  (3) the establishment and verification of relevant and 
20 appropriate performance specifications as defined under 
21 the federal Clinical Laboratory Improvement Amendments and 
22 regulations thereunder for Federal Drug 
23 Administration-cleared or in-house developed methods, 
 
 
HB2790- 2 -LRB099 03689 JLK 23700 b


1 performed under an institutional review board approved 
2 protocol, if required;
3  (4) the availability of quality assurance testing and 
4 comparative threshold values for ALD;
5  (5) the acquisition and installment by the Department 
6 of the equipment necessary to implement the initial pilot 
7 and statewide volume of screening tests for ALD;
8  (6) the establishment of precise threshold values 
9 ensuring defined disorder identification for ALD;
10  (7) the authentication of pilot testing achieving each 
11 milestone described in items (1) through (6) of this 
12 Section for ALD; and
13  (8) the authentication of achieving the potential of 
14 high throughput standards for statewide volume of ALD 
15 concomitant with each milestone described in items (1) 
16 through (6) of this Section.
17 The Department is authorized to implement an additional fee 
18for the screening prior to beginning the testing in order to 
19accumulate the resources for start-up and other costs 
20associated with implementation of the screening and thereafter 
21to support the costs associated with screening and follow-up 
22programs for adrenoleukodystrophy.